Bankruptcies reached a high not seen since 2011, with opioid lawsuits playing a big role.
News & Analysis: Mallinckrodt
These stocks skyrocketed during healthcare's biggest event of the year -- the J.P. Morgan Healthcare Conference.
Momentum from its CEO's comments earlier this week continues.
Investors appear to be optimistic about the drugmaker's impending Q3 update.
Investors continue to grapple with the uncertainty hanging over the company.
Upbeat news on interest rates and asset sales lifted these stocks on an otherwise tough day for the market.
The company is reportedly considering bankruptcy to cope with its financial exposure in the opioid crisis.
Worries about opioid litigation and a recent patent lawsuit loss continue to weigh on the drugmaker.
Find out how earnings affected some of these stocks.
The bad news keeps piling up.